The Osteoporosis Drugs Market to virtually grow beyond geographies

1. The Osteoporosis Drugs Market to virtually grow beyond geographies The Osteoporosis Drugs Market is all set to be in the driver’s seat shortly. Technology adoption once looked upon as a costly endeavor, is slated to witness a drastic transformation in the form of granular applications. Technologies like DevOps and AIOps are constructively disrupting the healthcare IT sector and are expected to create wonders in this regard in the upcoming period. The global osteoporosis drugs market is valued at US$ 12.5 Bn at present, and is expected to progress at a modest CAGR of 3.8% from 2021 to 2031, to account for US$ 18 Bn by 2031. To remain ‘ahead’ of your competitors, request for a sample @ https://www.persistencemarketresearch.com/samples/2983 The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market. However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits the growth of the market. Company Profiles: Eli Lilly and Company F. Hoffmann-La Roche Ltd. Merck & Co, Inc. Novartis AG Amgen, Inc. Novo Nordisk A/S Actavis plc Pfizer, Inc. GlaxoSmithKline plc Teva Pharmaceutical Industries Ltd Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

2. In North America, the prevalence of osteoporosis is high primarily due to increasing geriatric population, growing obesity, and rising prevalence of lifestyle associated diseases in the region. According to the U.S. Department of Health and Human Services, in the U.S., approximately 250,000 hip fractures are associated with osteoporosis. In Europe, increasing aging population, changing lifestyles, and increasing consumer awareness about osteoporosis care are driving the growth of the osteoporosis drug market. According to International Osteoporosis Foundation, approximately 27.5 million people in Europe suffered from osteoporosis in 2010, and the number is expected to reach 33.9 Mn by 2030. However, the growth of osteoporosis market in Asia Pacific is much due to rising geriatric population and changing lifestyles in the region. Osteoporotic patients have a higher risk of hip fractures, owing to a major cause of morbidity and mortality. According to the International Osteoporosis Foundation, by 2050, approximately 1/2 of the world’s osteoporosis hip fractures would occur in women in Asia. For in-depth competitive analysis, buy now @ https://www.persistencemarketresearch.com/checkout/2983 About Us: – Persistence Market Research Contact us: Persistence Market Research Address – 305 Broadway, 7th Floor New York City, NY 10007 United States

3. U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales– sales@persistencemarketresearch.com Website– https://www.persistencemarketresearch.com